Viz.ai has signed a multiyear agreement with Bristol Meyers Squibb to deploy its Viz HCM artificial intelligence (AI) workflow software for triaging patients who may require further evaluation for hypertrophic cardiomyopathy (HCM).
Viz HCM is intended to automatically review routine electrocardiograms (ECGs) from across a health system, identify suspected cases of HCM, and notify the appropriate cardiologist. The physician can then review the ECG in a timely manner and take the appropriate clinical action, including recommending follow-up diagnostic testing in parallel to the standard of care, Viz.ai said.
Viz HCM is currently under review at the U.S. Food and Drug Administration and will be integrated into the Viz.ai Cardio Suite for U.S. hospitals once cleared for use, the company said.
